Jove
Visualize
Contact Us

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.5K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.5K
Glaucoma: Overview01:25

Glaucoma: Overview

1.6K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retinal Functional and Structural Neural Indices: Potential Biomarkers for the Monitoring of Cerebral Neurodegeneration: The Maastricht Study.

Journal of Alzheimer's disease : JAD·2023
Same author

Low Vision Aids in Glaucoma.

Journal of current glaucoma practice·2016
Same author

Optical coherence tomography as a tool to evaluate retinal changes in Parkinson's disease.

Parkinsonism & related disorders·2015
Same author

Retinal oxygen saturation in retinitis pigmentosa and macular dystrophies in asian-Indian eyes.

Investigative ophthalmology & visual science·2015
Same author

Adaptive optics imaging of the retina.

Indian journal of ophthalmology·2014
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 9, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K

Bevacizumab in Glaucoma: Where do We Stand?

Anjani Khanna1

  • 1Glaucoma Services, Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India.

Journal of Current Glaucoma Practice
|December 29, 2016
PubMed
Summary

Antivascular endothelial growth factors (anti-VEGFs) like bevacizumab revolutionized ophthalmic treatments. This review explores their current clinical applications and knowledge gaps in managing glaucoma.

Area of Science:

  • Ophthalmology
  • Vascular Biology

Background:

  • Antivascular endothelial growth factors (anti-VEGFs), including bevacizumab and ranibizumab, have transformed ophthalmic disorder management.
  • Despite widespread use, a comprehensive understanding of anti-VEGFs in glaucoma is limited by a lack of large-scale randomized controlled trials.

Approach:

  • This review synthesizes current knowledge on the clinical applications of anti-VEGF agents in glaucoma.
  • It highlights existing gaps in understanding due to limited robust clinical data.

Key Points:

  • Anti-VEGF therapy represents a significant advancement in treating various eye conditions.
  • Further research, particularly large randomized controlled trials, is needed to fully elucidate the role of anti-VEGFs in glaucoma management.

Conclusions:

Keywords:
BevacizumabGlaucomaIntraocular pressureVEGF.

More Related Videos

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.8K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.6K

Related Experiment Videos

Last Updated: Mar 9, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.8K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.6K

  • Bevacizumab and ranibizumab show promise in ophthalmic applications.
  • More evidence is required to establish definitive clinical guidelines for using anti-VEGFs in glaucoma.